Compositions and methods for treating macular degeneration
First Claim
1. A pharmaceutical composition comprising a substituted C20-D1-3-retinoid and a pharmaceutically acceptable carrier, wherein the C20-D1-3-retinoid is selected from the group consisting of C20-D1-3-retinol, C20-D1-3-retinol ester, C20-D1-3-retinal and a C20-D1-3-pro-vitamin A carotenoid.
0 Assignments
1 Petition
Accused Products
Abstract
Methods of retarding formation of a lipofuscin pigment in the retina and of treating or ameliorating the effects of a disease characterized by an accumulation of a lipofuscin pigment in a retina are provided. These methods include the step of administering to a patient in need thereof a substituted C20-retinoid in an amount sufficient to reduce accumulation of a lipofuscin pigment in the retina. Further provided are methods of retarding formation of A2E and/or ATR-dimer by replacing an all-trans-retinal (ATR) substrate with a C20-D3-retinal substrate under conditions sufficient to impede the formation of A2E. Compositions for retarding formation of a lipofuscin pigment in the retina containing a substituted C20-retinoid and a pharmaceutically acceptable carrier are also provided.
26 Citations
28 Claims
- 1. A pharmaceutical composition comprising a substituted C20-D1-3-retinoid and a pharmaceutically acceptable carrier, wherein the C20-D1-3-retinoid is selected from the group consisting of C20-D1-3-retinol, C20-D1-3-retinol ester, C20-D1-3-retinal and a C20-D1-3-pro-vitamin A carotenoid.
Specification